Published in Blood Weekly, June 10th, 2004
After licensing the molecule from Dendreon Corp. in February 2004, Nuvelo took steps to reinitiate the study also referred to as ANTHEM (Anticoagulation with NAPc2 To Help Eliminate Mace)/TIMI 32. Prior to reinitiation, 77 patients had been enrolled in the trial. An additional 98 patients will be enrolled in this phase of the trial for a total of 175 patients in centers across the United States and Canada.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.